Oncolyze on SeedInvest 2022 – KingsCrowd

Oncolyze, with a valuation of $30 million, is elevating funds on SeedInvest by means of Reg A+ crowdfunding. It’s a biotech firm aiming to deal with most cancers by exploding most cancers cells. The primary goal demographic of Oncolyze is Acute Myelogenous Leukemia (AML), and its lead drug candidate, OM-301, has generated optimistic ends in treating AML. Oncolyze has efficiently accomplished in vitro and in vivo experiments and considerably will increase survival charges. OM-301 has additionally acquired Orphan Drug Designation from the FDA. Steven J. Evans based Oncolyze in 2011. The present crowdfunding marketing campaign has a most goal of $15,000,000. The marketing campaign proceeds might be used for pre-clinical and manufacturing, financing, personnel, and medical trials.